Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 213Myelodysplastic Syndromes 82Leukemia 44Leukemia, Myelomonocytic, Chronic 35Recurrence 16Myeloproliferative Disorders 15Neoplasm, Residual 10Lymphoma, T-Cell, Peripheral 10Leukemia, Biphenotypic, Acute 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large B-Cell, Diffuse 7Anemia, Refractory, with Excess of Blasts 7Primary Myelofibrosis 6Lymphoma, Non-Hodgkin 6Hodgkin Disease 6Congenital Abnormalities 6Lymphoma, T-Cell 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Polycythemia Vera 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Myeloid 4

Interventions

Carboplatin 75Paclitaxel 68Bevacizumab 44Taxes 22Cyclophosphamide 21pembrolizumab 19Gemcitabine 19Cisplatin 18Topotecan 17Hyperthermic Intraperitoneal Chemotherapy 14olaparib 13liposomal doxorubicin 13Immunoglobulin G 13Disulfides 13Specimen Handling 11Drug Therapy 11niraparib 10Cytoreduction Surgical Procedures 10Magnetic Resonance Spectroscopy 9sargramostim 7Surveys and Questionnaires 7Doxorubicin 7Docetaxel 7durvalumab 6Platinum 6Nivolumab 6Letrozole 6Granulocyte-Macrophage Colony-Stimulating Factor 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fallopian Tube Neoplasms × Azacitidine × Clear all
NCT00529022 2013-02-20

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
36 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡